| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Afacifenacin | R Afacifenacin | VL5500001 | View |
Afacifenacin Impurities
| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Afacifenacin | R Afacifenacin | VL5500001 | View |
| Catalogue No. | VL5500001 |
| CAS No. | N/A |
| Molecular Formula | C27H26F3N3O2 |
| Molecular Weight | 481.52 g/mol |
| Parent drug | Afacifenacin |
| IUPAC Name | (R)-(-)-3-[1-[3-(Trifluoromethoxy)benzyl]piperidin-4-yl]-4-phenyl-3, 4-dihydro-1H-quinazolin-2-one |
| Synonyms | N/A |
| Smiles | |
| References | Zinner, N, et al. “Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy.” International Journal of Clinical Practice, vol. 62, no. 11, 1 Nov. 2008, pp. 1664–1674, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680263/, 10.1111/j.1742-1241.2008.01893.x. |
| Status | Not Available |
| ListName | R Afacifenacin |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
